The flux of platelet agonists into flowing blood is a critical event in thrombosis and hemostasis. However, few in vitro methods exist for examining and controlling the role of platelet agonists on clot formation and stability under hemodynamic conditions. In this paper, we describe a membrane-based method for introducing a solute into flowing blood at a defined flux. The device consisted of a track-etched polycarbonate membrane reversibly sealed between two microfluidic channels; one channel contained blood flowing at a physiologically relevant shear rate, and the other channel contained the agonist(s). An analytical model described the solute flux as a function of the membrane permeability and transmembrane pressure. The model was validated using luciferase as a model solute for transmembrane pressures of 50-400 Pa. As a proof-of-concept, the weak platelet agonist ADP was introduced into whole blood flowing at 250 s -1 at three fluxes (1.5, 2.4, and 4.4 × 10 -18 mol µm -2 s -1 ). Platelet aggregation was monitored by fluorescence microscopy during the experiment and the morphology of aggregates was determined by post hoc confocal and electron microscopy. At the lowest flux (1.5 × 10 -18 mol µm -2 s -1 ), we observed little to no aggregation. At the higher fluxes, we observed monolayer (2.4 × 10 -18 mol µm -2 s -1 ) and multilayer (4.4 × 10-18 mol µm -2 s -1 ) aggregates of platelets and found that the platelet density within an aggregate increased with increasing ADP flux. We expect this device to be a useful tool in unraveling the role of platelet agonists on clot formation and stability. The flux of platelet agonists into flowing blood is a critical event in thrombosis and hemostasis. However, few in vitro methods exist for examining and controlling the role of platelet agonists on clot formation and stability under hemodynamic conditions. In this report, we describe a membrane-based method for introducing a solute into flowing blood at a defined flux. The device 10 consisted of a track-etched polycarbonate membrane reversibly sealed between two microfluidic channels; one channel contained blood flowing at a physiologically relevant shear rate, and the other channel contained the agonist(s). An analytical model described the solute flux as a function of the membrane permeability and transmembrane pressure. The model was validated using luciferase as a model solute for transmembrane pressures of 50-400 Pa. As a proof-of-concept, the 15 weak platelet agonist ADP was introduced into whole blood flowing at 250 sec -1 at three fluxes (1.5, 2.4, and 4.4 × 10 -18 mol μm -2 sec -1 ). Platelet aggregation was monitored by fluorescence microscopy during the experiment and the morphology of aggregates was determined by post hoc confocal and electron microscopy. At the lowest flux (1.5 × 10 -18 mol μm -2 sec -1 ), we observed little to no aggregation. At the higher fluxes, we observed monolayer (2.4 × 10 -18 mol μm -2 sec -1 ) 20 and multilayer (4.4 × 10 -18 mol μm -2 sec -1 ) aggregates of platelets and found that the platelet density within an aggregate increased with increasing ADP flux. We expect this device to be a useful tool in unraveling the role of platelet agonists on clot formation and stability.
consisted of a track-etched polycarbonate membrane reversibly sealed between two microfluidic channels; one channel contained blood flowing at a physiologically relevant shear rate, and the other channel contained the agonist(s). An analytical model described the solute flux as a function of the membrane permeability and transmembrane pressure. The model was validated using luciferase as a model solute for transmembrane pressures of 50-400 Pa. As a proof-of-concept, the 15 weak platelet agonist ADP was introduced into whole blood flowing at 250 sec -1 at three fluxes (1.5, 2.4, and 4.4 × 10 -18 mol μm -2 sec -1 ). Platelet aggregation was monitored by fluorescence microscopy during the experiment and the morphology of aggregates was determined by post hoc confocal and electron microscopy. At the lowest flux (1.5 × 10 -18 mol μm -2 sec -1 ), we observed little to no aggregation. At the higher fluxes, we observed monolayer (2.4 × 10 -18 mol μm -2 sec -1 ) 20 and multilayer (4.4 × 10 -18 mol μm -2 sec -1 ) aggregates of platelets and found that the platelet density within an aggregate increased with increasing ADP flux. We expect this device to be a useful tool in unraveling the role of platelet agonists on clot formation and stability.
Introduction
During thrombus formation on the exposed subendothelial 25 matrix, platelets pause or roll on von Willebrand factor, and then arrest and activate on collagen 1, 2 . Adhered platelets become activated through outside-in signaling via glycoprotein receptors 3 . Activated platelets recruit and aggregate other platelets by producing soluble agonists and 30 releasing them into the flowing blood. These agonists include, but are not limited to, thrombin 4 , ADP 5 , and thromboxane A 2 6 .
The cellular and molecular events of platelet adhesion to surface-bound proteins and subsequent platelet activation has been extensively studied in animal [7] [8] [9] and in vitro models 10-14 .
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In vitro models have been critical in defining the shear dependent bonding dynamics between platelet receptors and their surface bound ligands. Parameters such as on and off rates and adhesion efficiency have been measured by manipulating the composition and density of surface-bound 40 ligands 15 . However, there are no in vitro models for manipulating agonist flux into flowing blood.
In this report, we describe a membrane based microfluidic device for controlling the flux of platelet agonists into flowing whole blood. The device consists of two channels separated 45 by a membrane. One channel contains blood flowing at a physiologically relevant mean wall shear rate (250-2000 sec -1 ). The second channel, containing the agonist(s), is oriented perpendicular to the first channel. At the intersection of the two channels, the flux of agonists into flowing blood is 50 controlled by the concentration of the agonist and the transmembrane pressure. Luciferase was used as a model solute to examine the roles of wall shear rate, the relative flow rates of the two channels, and protein fouling on flux. Analytical and numerical models were developed to describe 55 the fluid flow and mass transport in the device. As a proof-ofconcept, the platelet agonist ADP was introduced at three different molar fluxes into flowing whole blood. Post hoc electron and confocal microscopy reveal that platelet activation and aggregation depend on the magnitude of ADP 60 flux. This is the first demonstration of user-controlled ADP wall flux into flowing blood to trigger platelet deposition. Figure 1a illustrates the three layers of the device; 1) a top 65 channel that contains flowing blood, 2) a track-etched polycarbonate membrane, and 3) a bottom channel that contains the agonist solution and a vacuum chamber. The channels were made by (poly)dimethlysiloxane (PDMS) molding techniques 16 . Briefly, a high aspect ratio negative 70 photoresist (KMPR 1050, MicroChem Corp., Newton, MA) was spun and patterned on a silicon substrate at a height of 100 μm. Microfluidic channels had a cross-sectional area of 100 μm × 100 μm. In the bottom layer the channel was separated by a solid barrier from the vacuum chamber. An 75 array of 400 μm posts spaced 1 mm apart was used to prevent collapse of the vacuum chamber under negative pressure (Figure 1c ). The bottom channel was a single mold process, PDMS mold off of a photoresist master. The top channel and vacuum chamber required a two mold process, with an additional PDMS mold off a PDMS master. We found the two mold process to provide better pattern transfer of the pillars than a single mold process. Inlet and outlet holes were created 5 in the PDMS using sharpened 23 gauge stainless steel tubing. Small diameter tubing (PEEK, ID=150 μm, OD=360 μm, Upchurch Scientific, Oak Harbor, WA) was used to make external connections to reservoirs of agonist(s) and blood solutions and withdrawal syringes. A compression fitting for 10 connection to the PDMS was made by gluing a larger diameter sleeve (PEEK, ID=380 μm, OD=1/16 inch) over the end of the small diameter tubing. One foot of tubing was used for all four connections, inlet and outlet of both channels. The total dead volume in the tubing for each channel was 11 μL.
Experimental

Device fabrication and operation
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The flow rate of the top and bottom channels were independently controlled with two syringe pumps (PHD 2000, Harvard Apparatus, Holliston, MA) driving glass syringes (100 μL and 250 μL, Hamilton Co. Reno, NV). The device was assembled by placing a track-etched polycarbonate 20 membrane (13 mm diameter, B1013-MB, Structure Probe, Inc., West Chester, PA) onto a 10 mm platform on the bottom PDMS layer. The bottom and top layers were aligned by hand using a low magnification stereoscope, brought into contact, and vacuum sealed at a pressure of ~40 kPa using a diaphragm 25 pump (DOA-V163-BN, Gast Manufacturing, Inc., Benton Harbor, MI). By design, there was a thin gap between the two PDMS layers at the periphery of the membrane. During the flow experiments, fluid slowly escaped through this gap into the vacuum chamber. Less than 10 μL of fluid was lost 30 through the gap over one hour. Since the membrane area is larger than the PDMS platform there is no crosscontamination between the two fluid streams. At high wall shear rates (1000-2000 sec -1 ) both the blood and agonist reservoirs were at atmospheric pressure and were withdrawn 35 (negative pressure) via the syringe pumps. In some experiments at low all shear rates (250-500 sec -1 ), the agonist solution was infused (positive pressure) and the blood solution withdrawn (negative pressure) to a achieve higher transmembrane pressure. 
Agonist flux models
Solute flux through the membrane into a flowing solution is determined by the solute properties (size, shape, charge), the pore characteristics of the membrane (radius, length, pore density), and the operating conditions (concentration gradients 45 and pressure gradients). Within the blood containing channel, the constant flux of agonist leads to the formation of a boundary layer which begins at the upstream edge of the reaction zone. The thickness of the boundary layer determines how many platelets experience threshold concentrations of an 50 agonist and thus are activated. We developed two models to capture each of these events; 1) an analytical model which describe the flux of a solute through the membrane and 2) a finite element model to capture the fluid dynamics and transport within the microfluidic channels. 
Analytical Model of Agonist Flux
As a first-order estimate, we treated the membrane as a porous medium that uniformly experiences the same pressure drop across the entire length and width of the membrane (100 μm × 60 100 μm) at the intersection between the two channels. The transmembrane pressure was obtained by first calculating the pressure in each channel and then subtracting the difference between the two channels at the intersection point. Owing to the small diameter of the PEEK tubing used in the 65 experiments, we also accounted for the pressure drop through the tubing, which in some cases was a significant fraction of the overall pressure drop. We analytical expressions to find the pressure drop through a rectangular channel per unit length and the wall shear rate 17 :
where P is pressure, L is channel length, v is the mean velocity, μ is viscosity, h is channel height, ε is the channel aspect ratio. The mean velocity was set to achieve a desired mean wall shear rate:
where γ wall is the mean wall shear rate, A is the channel crosssectional area, f is the Fanning friction factor, and Re is the Reynolds number based on a characteristic length of A. To 80 find the transmembrane pressure, eq. 1 was evaluated at the half length of both channels (including tubing):
where ΔP membrane is the transmembrane pressure, and P 1,L/2 and P2 ,L/2 is the pressure in channel 1 and 2, respectively, at the 85 half length of the channel. The specific discharge of agonist from channel 2 into channel 1 was calculated using Darcy's law and the experimentally determined hydraulic permeability (see section 2.3.1):
where v a is the agonist velocity through a single pore, k is the Darcy's permeability, and t is the membrane thickness. The unhindered agonist flux was calculated by considering both diffusive and convective transport through the membrane:
where J a is the agonist flux, D ∞ is the agonist diffusion coefficient in water, c a is the agonist concentration, and v a is the mean velocity. In the membranes used in this report the agonist was much smaller than the pore (r agonist /r pore <0.01), so there were no steric hindrances to transport 18 . We assume that the concentration in the top channel is zero, so that the concentration gradient across the membrane is ∇c a =(c a,2 -0)/L. This assumption overestimates the agonist flux because the concentration at the wall in the top channel is nonzero. However, in most cases the device is operated at a pore Peclet 5 number (Pe=v a L/D) greater than 10 and therefore the contribution of the diffusive flux to the overall flux is small (<10%).
Finite Element Model of Agonist Flux and Distribution
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A two-dimensional model of fluid flow and agonist transport was developed using commercial finite element software (COMSOL Multiphysics, Burlington, MA). The model geometry consists of two parallel channels, each with a height of 100 μm and a length of 18. in the bottom channel had the physical properties of water and the diffusivity of ADP was estimated using the Wilke-Chang correlation 20 .
The mesh consisted of 303,616 triangular elements. Mesh independence was evaluated by comparing the concentration 25 profiles for grids consisting of 206,436, 303,616 and 375,122 elements. There was no greater than 2% difference in the magnitude of the concentration between the three grid sizes at any position within the simulation geometry. The steady state mass and momentum conservation equations were solved in 30 28 minutes using a linear systems solver (UMFPACK) on a Linux workstation (dual 2.2 GHz processors, 12 GB RAM).
Device characterization
Membrane hydraulic permeability
The hydraulic permeability for membranes with a pore 35 diameter of 0.6 μm and 1 μm and three surface conditions (no coating, BSA coated, fibrinogen coated) was determined by measuring the flow rate through the membrane under a constant pressure head. Protein coatings were achieved by incubation of 1 mg/ml BSA or 0.1 mg/ml fibrinogen for two 40 hours at room temperature followed by thorough rinsing in deionized water. Wet membranes were mounted in a filter holder (F0101-BA, Structure Probe Inc., West Chester, PA, USA). A constant pressure head was provided in a 60 mL syringe attached to the top of the filter holder. The flow rate 45 was determined by measuring the weight of the permeating deionized water after 5 minutes on a top loading balance.
Water levels of 1.5, 2, and 2.5 inches of water (373, 500, 627 Pa) were maintained for 5 minutes for 0.6 μm membranes. Water levels of 1.5, 2, and 3 inches of water 50 (373, 500, 750 Pa) were maintained for 5 minutes for 0.6 μm membranes. Each measurement was performed in triplicate with a different membrane.
These pressure drops are comparable to those across the membrane within the device. Using Darcy's Law (v=k/μ∇P), the permeability was 55 calculated by a least square fit of the data Q/A versus P/t, where Q is the flow rate in m 3 /s, A is the membrane area in m 3 , P is the pressure drop in Pa, and t is the thickness in m.
Previous reports showed that water flux decreases with time for track-etched polycarbonate membranes. In a second set of 60 experiments, we measured the permeability as function of time over 25 minutes at each pressure (250, 500, 750 Pa).
Luciferase molar flux
The molar flux was adjusted by changing the wall shear rate 65 in the top channel, the relative flow rate (Q1/Q2), and agonist concentration. We used firefly luciferase (61 kDa) as model agonist and measured the flux through a polycarbonate membrane with an average pore diameter of 1 μm. The flow rate in the top channel was set to mean wall shear rates of PerkinElmer, Waltham, MA). An automated dispenser in the plate reader injected each well with 100 μL of substrate (E4550, Promega Corp., Madison, WI) followed immediately by reading the luminescence signal for 10 seconds. Luciferase concentration was calculated by integrating the luminescence 95 signal for nine seconds and comparing the integrated signal to a standard curve. A standard curve was generated for each plate over the linear range (10 fM to 1 nM) of the luminescence assay. The luciferase flux was calculated by multiplying the concentration by the flow rate and dividing by 100 the cross-sectional area (100 μm × 100 μm) where the two channels intersect. Each experimental condition was run in triplicate on a separate membrane. Membranes used for protein filtration are known to foul over time, which can lead to diminished water and solute 105 flux 21, 22 . We investigated the role of fouling in this system by measuring luciferase flux at different transmembrane pressures over 25 minutes. The experimental conditions were 1 nM luciferase and 1 mg/mL BSA in PBS in the bottom channel, 1 mg/mL BSA in PBS in the bottom channel, 110 Q1/Q2=10 for mean wall shear rates of 2000 sec -1 and 1000 sec -1 , Q1/Q2=0.5 for mean wall shear rates of 500 sec -1 and 250 sec -1 in the top channel. Fractions were collected every 5 minutes, diluted to a total volume of 100 μL, and the flux was determined following the procedure above. 
Introduction of ADP into flowing whole blood
Human whole blood was obtained from healthy volunteers via venipuncture and anticoagulated with sodium citrate (9 parts blood to 1 part sodium citrate) and corn trypsin inhibitor (50 μg/ml final concentration) to block Factor XIIa and associated intrinsic pathway initiation. Platelets were incubated for five 5 minutes with an anti-CD41:Alexa 647 antibody (MCU467A647, AbD Serotec, Releigh, NC) at a volume ratio of 50 parts blood to 1 part antibody. Immediately before introduction into the device, the blood was recalcified with CaCl 2 (100mM in HEPES buffered saline) to a final calcium 10 concentration of 20 mM. The blood was withdrawn to achieve a mean wall shear rate of 250 sec -1 for five minutes. ADP (10 μM) in HEPES buffered saline (HBS) was perfused at relative flow rates of Q1/Q2=0.075, 0.15, 0.3 corresponding to transmembrane pressures of 1020, 545, and 308 Pa, 15 respectively. After five minutes, the blood was replaced with HBS and the adhered platelets were washed for five minutes at a mean wall shear rate of 100 sec -1 . Each experimental condition was run in triplicate with blood from a different donor. The platelet count for each donor was measured using 20 a Coulter counter.
The device was operated as described in section 2.3.2, except that the polycarbonate membrane was incubated in 0.1 mg/mL human fibrinogen for 2 hours. Adsorbed fibrinogen is amenable to activated platelet adhesion through the α IIb β 3 25 integrin, but does not result in quiescent platelet adhesion at the shear rates in this report 23 . Before introducing blood and agonists into the device, the channels were filled with 1 mg/ml BSA solution in HBS buffer and allowed to flow for 10 minutes at Q1/Q2=1. 30 
Post hoc electron and confocal microscopy
Immediately following a flow experiment, the device was dismantled and the membrane was thoroughly washed in HBS buffer. The sample was fixed in 2% glutaraldehyde for four hours at room temperature and overnight at 4 ºC. The samples 35 were stored in 0.1 M sodium cacodylate buffer at 4 ºC until processing. The day of imaging, the samples were dehydrated for 15 minutes in graded ethanol solutions of 50%, 70%, 80%, 90%, and twice in 100%. For electron microscopy, the samples were then critical point dried and sputtered with 40 Au/Pd. Samples were imaged on a field emission scanning electron microscope (Supra 50VP, Carl Zeiss SMT, Oberkochen, Germany) at an accelerating voltage of 5 kV. For fluorescence microscopy, the samples were coverslipped in mounting medium (H-100, Vector Laboratories, Burlingame, 45 CA) and imaged using a 60x oil immersion objective on a spinning disk confocal fluorescence microscope (IX81-DSU, Olympus America, Center Valley, PA).
To estimate the role of ADP flux on platelet aggregation, we calculated the platelet surface and volume density in 50 aggregates for the different experimental conditions. For each membrane, the integrated fluorescence intensity of single platelets (n=10) was measured as a baseline value (F o ). The integrated fluorescence intensity of each aggregate (F a ) was divided by the baseline single platelet value to yield the 55 number of platelets per aggregate (N=F a /F o ). We defined the platelet surface density as the number of platelets per aggregate divided by the aggregate area ( N =N/A a ). We only considered platelet aggregates formed in the first 200 μm downstream from the reaction zone. The platelet volume 60 density within an aggregate was measured by dividing the surface density by the confocal stack height, which ranged from 4-8 μm.
Results
Device Characterization
65
A three layer device consisting of two perpendicular channels and a membrane was fabricated for controlling the flux of platelet agonists into blood flowing at physiological shear rates (Figure 1) . The three layers were reversibly sealed during operation by vacuum-assisted bonding. The agonist 70 flux was a function of the membrane properties, the relative flow rate of the two channels (Q1/Q2), and the agonist concentration in the bottom channel. The  permeability  was  measured  for  track-etched   75 polycarbonate membranes with pore diameter of 0.6 and 1 μm. Table 1 shows the permeability of membranes with these two pore diameters for no surface treatment, adsorbed BSA, and adsorbed fibrinogen. Figure S1 shows the velocity as a function of pressure and least squares fit used to determine 80 permeability. There is approximately a four-fold smaller permeability of the 0.6 μm pore membranes than the 1.0 μm pore membrane (k 1μm /k 0.6μm ≈4). For a porous medium with straight cylindrical pores, like track-etch polycarbonate, the permeability is proportional to the pore density and the pore 85 diameter to the fourth power (k α N d pore 4 ) 24 . The manufacturer reports a pore density of 2 × 10 7 pores/cm 2 for 1 μm pore diameter membranes and 3 × 10 7 pores/cm 2 for 0.6 μm pore diameter membranes. Therefore, the ratio of the permeabilities between the two membranes should be 90 k 1μm /k 0.6μm =5.1. However, this estimate does not account for dispersity of pore sizes and non-parallel pores, both of which could lead to a lower permeability.
Membrane hydraulic permeability
For a pore diameter of 1 μm there was no significant change in the permeability for all three surface conditions. 95 There was a 43% decrease in permeability for fibrinogen treated 0.6 μm pore membranes and no change for BSAtreated membranes. Based on these results, we chose to use the 1 μm pore membranes for device characterization and blood experiments since there was no change in permeability 100 between BSA and fibrinogen surface treatments.
Previous reports have shown a decrease in water flux with time for track-etched polycarbonate membranes 24, 25 . Figure  S2 shows the decline in water flow rate for membranes with a 1 μm average pore diameter as function fo time. For constant 105 pressure heads of 250, 500, and 750 Pa there was a 11.0%, 10.5%, and 4.4% decline in water flux over 25 minutes, respectively. The flux decline may be due to particulates in the water and bubbles forming within the pores. Mueller and Davis reported a 41-60% water flux decline in track-etched 110 polycarbonate membranesover the same time, albeit for smaller pores (0.2 mm) and much larger pressures (69,000-138,000 Pa) 25 .
Luciferase molar flux
The agonist flux was manipulated by varying three parameters; relative flow rate, wall shear rate, and agonist concentration. Varying the relative flow rate and wall shear rate were both methods for changing the pressure drop across there were several multilayer aggregates.
Discussion
Platelet adhesion to surface-bound protein on the subendothelium is the initial condition of blood coagulation.
105
Following adhesion, the platelets become activated and in turn generate thrombin and thromboxane A 2 on their extracellular membranes and release ADP from intracellular stores to promote further platelet activation and aggregation. The release of these platelet agonists into the blood flowing over 110 the adhered platelets is the boundary condition that leads to platelet aggregation. The flux of these three agonists into flowing blood serves an important role in thrombosis and hemostasis. However, the combined function of such soluble agonists during clot formation under flow is unknown, since no method allows controlled fluxes of agonists into flowing blood. The relationship between solute flux and stable clot formation is a complex reaction-transport problem with coupled particle deposition. One example of altered solute 5 flux is hemophilia, where deficiencies in clotting factors attenuates thrombin generation 26 , which leads to unstable clots 27 . It is less clear whether these clots are unstable because of diminished fibrin formation or diminished platelet activation, or both. The device described in this report 10 provides a method for manipulating solute flux that could be useful for studying hemophilia and other bleeding disorders.
The size and growth of a thrombus is limited by the interplay between activated platelets and intact endothelial cells. Endothelial cells secrete soluble molecules (nitric 15 oxide, prostacyclin, ecto-necleotidases) that control platelet reactivity in a process known as thromboregulation 28 . The device presented in this report could be extended to study thromboregulation with additional bottom channels for introduction of these platelet antagonists. 20 Incorporation of membranes into microfluidic devices is becoming increasingly common for on-chip filtration and separations, as well as a component for sensors, reactors, and cell culture 29 . on the order of 100's microns, whereas the polycarbonate membranes are 5-15 μm thick. The membrane thickness is an important parameter in the multilayer device described in the manuscript.
We attempted to use a cellulose acetate membrane (thickness=110 μm) and found that the loss of fluid 55 into the vacuum chamber was prohibitive. Solute transport was accurately predicted with an analytical model when convection was the dominant transport mechanism within the pores (Pe>10). Although the model did not account for protein fouling, it was a good first-order 60 etstimate of flux that only required two parameters, the membrane permeability and transmembrane pressure. The device was operated in two configurations that depended on the wall shear rate in the top channel. At higher wall shear rates (1000-2000 sec -1 ), there was a large enough 65 transmembrane pressure generated by the top channel to achieve predominantly convective transport in the pores. At these high shear rates, fluid was withdrawn (negative pressure) from both channels. At lower wall shear rates (250-500 sec -1 ), the transmembrane pressure generated by the top 70 channel was insufficient to ensure convective transport. Therefore, at these low shear rates, the bottom channel was infused (positive pressure) to compensate for small pressure drop in the top channel. In some applications, such as gradient generation, diffusion-mediated transport may be preferable.
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This mode of operation is achievable by withdrawing fluid from both channels at the same flow rate, provided the channels have the same length and cross-sectional area.
As a demonstration of the device, we examined the dependence of platelet aggregation on ADP flux. We observed 80 that platelet activation, aggregation size, and aggregation height depended on the magnitude of ADP flux. At the lowest ADP flux considered, there was sparse adhesion of platelets and little evidence of aggregation and platelet-platelet tethering. At the higher fluxes, we observed aggregates of 85 hundreds of activated platelets. The size and height of aggregates increased with increasing ADP flux. These observations agree with previous reports that platelet adhesion efficiency to fibrinogen coated surfaces increases with ADP induced activation 23 . In addition, computational studies 90 predict that a thicker agonist boundary layer yields greater platelet aggregation [35] [36] [37] . In these computational studies, boundary layer thickness and thus platelet aggregation was modulated by changing the wall shear rate. However, increasing the agonist flux has a similar effect to decreasing 95 the wall shear rate.
Conclusions
We have fabricated and characterized a membrane-based microfluidic device for controlling the flux of platelet agonists into flowing blood. The molar flux of luciferase was 100 accurately predicted at high pore Peclet numbers using an analytical model. The introduction of ADP (1.5-4.4 × 10 -18 mol μm -2 sec -1 ) into flowing whole blood resulted in flux dependent platelet aggregation and activation. We expect this device will be a useful tool in unraveling the role of platelet 105 agonists on clot formation and stability.
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Notes and references
Fig S1
The hydraulic permeability of track-etched polycarbonate membranes was determined by a least squares fit of the velocity versus pressure drop (eqn. 5). Surface treatments of BSA and fibrinogen did not affect the permeability of membranes with a pore diameter of 1 μm. Fibrinogen treatment, but
Fig. S2
The water flux through a track-etched polycarbonate membrane with a pore diameter of 1 mm. For constant pressure heads of 250, 500, and 750 Pa there was a 11.0%, 10.5%, and 4.4% decline in water flux over 25 minutes.
